MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - October 05, 2012) - MorphoSys AG /
MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase
Clinical Trial in Pancreatic Cancer Processed and transmitted by Thomson
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
collaboration partner OncoMed Pharmaceuticals has advanced the HuCAL
OMP-59R5 into the next stage of clinical development. OMP-59R5, which is
OncoMed's Notch pathway collaboration with GlaxoSmithKline, is now
evaluated in a Phase 1b/2 trial in the US in first-line advanced
"We are excited to see this innovative HuCAL program advancing into the
stage of clinical development. Today's news further underlines that
pipeline has matured substantially and is today well balanced with
mid- to late-stage clinical development," commented Dr. Marlies
Sproll, Chief Scientific Officer of MorphoSys AG. "OMP-59R5 represents the
advanced HuCAL-based antibody program targeting a validated cancer stem
pathway. Cancer stem cells potentially offer one of the most attractive
for attacking a range of tumor types, making this program an exciting
to the overall pipeline of HuCAL-based drugs."
In the Phase 1b/2 "ALPINE" trial (Antibody therapy in first-Line
cancer Investigating anti-Notch Efficacy and safety), OMP-59R5 is being
in combination with gemcitabine in first-line advanced pancreatic
patients. Following a Phase 1b safety run-in, a randomized Phase 2
trial will proceed in these patients to compare the efficacy of
gemcitabine either with OMP-59R5 or with placebo. The primary endpoints
Phase 2 part of the trial will be progression-free survival (PFS) in
arms compared to a placebo arm. The two primary endpoints will examine
all patients, as well as in patients who have a particular
secondary and exploratory endpoints include overall survival, response
safety, and these endpoints will be assessed in all patients, as well as
biomarker positive subset of patients.
MorphoSys's clinical pipeline now comprises one program in phase 2/3
development, nine in phase 2 and eleven in phase 1. Of these,
proprietary, as yet un-partnered programs, namely MOR103, which has
completed a phase 1b/2a trial in rheumatoid arthritis and a phase 1b
multiple sclerosis, MOR208, which has completed a phase 1 trial for
lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
and Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE